Lead is considered a causative factor for hypertension and other cardiovascular diseases. Aims: To investigate the effects of sub-chronic lead exposure on blood pressure reactivity and cardiac β 1 -adrenoceptor activity and to evaluate whether the effects found in vitro are similar to those found in vivo. Main methods: Male Wistar rats were randomly distributed into two groups: control rats (Ct) and rats administered drinking water containing 100 ppm lead (Pb) for 30 days. Key findings: Blood pressure in the Pb rats increased starting from the first week of treatment until the end of the study [systolic blood pressure, Ct: 122 ± 4 vs. Pb: 143 ± 3 mmHg; diastolic blood pressure, Ct: 63 ± 4 vs. Pb: 84 ± 4 mmHg]. The heart rate was also increased (Ct: 299 ± 11 vs. Pb: 365 ± 11 bpm), but the pressure reactivity to phenylephrine was decreased. Losartan and hexamethonium exhibited a greater reduction in blood pressure of Pb rats than in the Ct rats. Isoproterenol increased the left ventricular systolic and end-diastolic pressure, and heart rate only in Ct rats, suggesting that lead induced β 1 -adrenoceptor downregulation. Indomethacin reduced the blood pressure and heart rate in the Pb rats, suggesting the involvement of cyclooxygenase-derived products (which are associated with reduced nitric oxide bioavailability) in this process. Significance: These findings offer further evidence that the effects of sub-chronic lead exposure in vitro can be reproduced in vivo-even at low concentrations-thus triggering mechanisms for the development of hypertension. Therefore, lead should be considered an environmental risk factor for cardiovascular disease.
Introduction
Cardiovascular diseases are the main cause of mortality and morbidity in several countries worldwide [1] . In addition, exposure to toxic agents, such as lead and other heavy metals, might contribute to the onset or aggravation of different cardiovascular diseases [2] [3] [4] [5] .
We recently reported that lead plays a role in the development of hypertension related to the increased activity of cyclooxygenase (COX) [6, 7] , angiotensin converting enzyme (ACE) and Na + -K + -ATPase [7] [8] [9] . Furthermore, lead promotes oxidative stress by increasing the production of reactive oxygen species (ROS) [10] , decreasing nitric oxide (NO) bioavailability and raising the endothelin levels [6, 11] . Previous studies have suggested that lead induces peripheral and central sympathetic hyperactivity, thus increasing vascular and cardiac adrenergic receptors stimulation and producing baroreflex hyposensitivity and vagal parasympathetic hypotone [12] [13] [14] . Recently, using rats that were acutely exposed to 320 μg/kg Pb i.v. in vivo and in vitro, Fioresi et al. [15] 
demonstrated that lead increases Life Sciences 180 (2017) 93-101
Abbreviations: BP, blood pressure; Ct, control group; Pb, lead treated group; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; COX, cyclooxygenase; NO, nitric oxide; ACE, angiotensin converting enzyme; ROS, reactive oxygen species; IP, intraperitoneal; L-NAME, N G -nitro-L-arginine methyl ester; NOS, nitric oxide synthase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; R max , the maximal effect for concentration-response curve; log EC50, the agonist concentration that produced 50% of the maximal response; -log EC50, agonist sensitivities are expressed as pD2; dAUC, difference in the area under the curve; AUC, area under the curve; SEM, mean standard error; LVSP, left ventricular systolic pressure; LVEDP, end-diastolic pressure; dP/dt + LV, left ventricular positive derivate; dP/dt-LV, left ventricular negative derivate; RAS, renin-angiotensin system; IV, intravenous; ATSDR, Agency for Toxic Substances and Disease Registry; BLL, blood lead level; CSTE, Council of State and Territorial Epidemiologists; KCl, potassium chloride; NPS, sodium nitroprusside; NADPH, reduced nicotinamide adenine dinucleotide phosphate oxidase; COX-2, cyclooxygenase 2; MAPK, mitogen activated protein kinases.systolic left and right ventricular pressures and produces positive inotropic and lusitropic effects in cardiac muscle. Carmignani et al. [13] also reported a positive cardiac inotropic effect in rats that were exposed to 60 ppm of lead acetate for 10 months; moreover, these authors showed increased ACE activity. The positive inotropic effects agree with the increased sympathetic hyperactivity and enhanced β-adrenergic stimulation on the heart that have been previously described [12] [13] [14] .
The putative role of lead exposure triggering mechanisms for increased blood pressure (BP) has been suggested by in vitro studies [8, 10, 16] . However, the role of lead in those mechanisms is not completely understood, and little is known about the in vivo hemodynamic effects of lead exposure [6, 8, 10] . Only a few studies have investigated the effects of lead with experimental protocols in vivo. Our aim was to study rats receiving 100 ppm lead in their drinking water over 30 days to evaluate whether the effects found in vitro are similar to those found in vivo. We performed hemodynamic protocols in chronically exposed rats at low lead concentrations and evaluated the mechanisms involved in the changes produced by this exposure as well as in the modulation of β 1 -adrenergicreceptors.
Materials and methods

Animals and lead exposure protocol
Male Wistar rats (two months old, initial weight 200-250 g) were randomly divided into two groups: rats provided drinking water containing 100 ppm lead acetate (Pb) and rats provided untreated water as a control (Ct). All the animals were treated for a period of 30 days. Rats were housed in conditions with constant temperature (22°C), humidity, and light cycle (12:12-h light-dark) with free access to water and rat chow ad libitum. Lead treatment did not affect weight gain (data not shown).
All experiments were conducted in compliance with the Guidelines for Biomedical Research as stated by the Brazilian Societies of Experimental Biology. The experimental protocols used in this study conform to the principle ethics of animal experimentation adopted by the Research Ethics Committee with Experimental Animals of the Federal University of Espírito Santo (CEUA/UFES), who have registered this study under number 014/2012.
Blood pressure measurement
Systolic blood pressure (SBP) in both groups was assessed weekly by tail plethysmography (IITC Life Science non-invasive blood pressure amplifier, version 1.35, Woodland Hills, CA, USA) according to the manufacturer's recommendations. Before initiating the BP measurements, the animals were subjected to an acclimatization period of three days. This adaptation was performed by placing the animal in the apparatus and exposing them to the BP measurement technique to reduce animal stress. SBP was reported as the arithmetic mean of three recorded measurements.
Hemodynamic measurements
After 30 days of treatment, the animals were anesthetized with urethane (1.2 mg/kg, intraperitoneal (IP)), the carotid artery was cannulated to measure the arterial pressure and the jugular vein was cannulated with a polyethylene catheter (PE-50/Clay-Adams) filled with heparin (50 U/mL) in saline for drug infusion. The arterial cannulae were connected to pressure transducers (TSD 104A-Biopac Systems, Inc.; CA, USA) connected to a preamplifier and an acquisition system (MP 30 Biopac Systems, Inc.; CA, USA) for recording pressure measurements. After 20 min of stabilization, the SBP, diastolic blood pressure (DBP) and heart rate (HR) were recorded. Then, the effects of the following drugs on those parameters were analyzed: hexamethonium (20 mg/kg), a ganglionic blocker; losartan (10 mg/kg), an AT 1 receptor antagonist; indomethacin (0.1 mg/kg), a non-selective COX inhibitor; isoproterenol, a β 1 -adrenoceptor agonist (10 mg/kg); and N G -nitro-Larginine methyl ester (L-NAME, 3 mg/kg), a non-selective nitric oxide synthase (NOS) inhibitor.
Pressure reactivity refers to the ability of vascular smooth muscle to present different vasoconstrictor responses upon exposure to different doses of an adrenergic agonist. To evaluate the blood pressure reactivity, increasing doses of the α 1 -adrenergic agonist phenylephrine were administered (0.03 to 100 mg/kg in a volume of 5 μL/100 g) to obtain a dose-response curve. After recording the hemodynamic parameters, the first dose-response curve of phenylephrine (control curve) was obtained. Then, one of the drugs was infused, and after 30 min of stabilization, a second dose-response curve to phenylephrine was recorded.
Finally, heart tissues were stored at − 80°C until further use for biochemical measurements.
Western blot analysis
The hearts were homogenized, and proteins (80 mg) were separated on 10% SDS-PAGE gels to evaluate β 1 -adrenergic receptor expression. The proteins were transferred to nitrocellulose membranes, which were first incubated with rabbit monoclonal antibodies targeting β 1 (1:1000, Thermo Scientific, Rd., Rockford, USA). Second, after the membranes were washed, they were incubated with an anti-rabbit secondary immunoglobulin antibody (1:5000, Sigma Chemical, Co, St. Louis USA) conjugated with horseradish peroxidase. Third, after a thorough washing, the immune complexes were detected using an enhanced horseradish peroxidase/luminal chemiluminescence system (ECL Plus, Amersham International, Little Chalfont, UK) and film (Hyperfilm ECL International). Signals on the immunoblot were quantified with the National Institutes of Health Image V1.56 computer program. Fourth, the same membrane was used to determine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression with a rabbit monoclonal antibody (1:5000, Sigma Chemical, CO, St. Louis, USA). Fifth, and after the membrane was washed, it was incubated with the anti-rabbit secondary antibody (1:5000, Sigma Chemical, Co, St. Louis, USA).
Chemicals
The following drugs were used: heparin (Roche Q.F.S.A., Brazil), urethane, bovine serum albumin, hexamethonium hydrochloride, indomethacin, isoproterenol, phenylephrine, lead acetate, L-NAME and losartan (Sigma Chemical Co., USA). All other reagents used were of analytical grade from either Sigma (St. Louis, USA) or E. Merck (Germany).
Data analysis and statistics
The percentages of the maximal response induced by phenylephrine were used to express the contractile responses. For each dose-response curve, the maximal effect (R max ) and the agonist concentration that produced 50% of the maximal response (log EC 50 ) were calculated using nonlinear regression analysis (GraphPad Prism, GraphPad Software, Inc., San Diego, CA, USA). The agonist sensitivities are expressed as pD2 (− log EC50). To compare the effects of the drugs on the arterial pressure responses to phenylephrine, some results were expressed as differences in the areas under the dose-response curves (dAUC) in both the control and experimental groups. AUCs were calculated from individual concentration-response curve plots: the differences are expressed as the percentage of the control AUC. For protein expression, the data are expressed as the ratio of the band intensities on the immunoblot corresponding to the protein of interest and GAPDH.
Results were analyzed using the unpaired Student's t-test and the one-or two-way ANOVA with repeated measures. When a significant one-way ANOVA was obtained, the Tukey post hoc test was used. For two-way ANOVA, the Bonferroni post hoc test was used. Differences were considered statistically significant at P b 0.05. The results are expressed as the mean ± standard error of the mean (SEM) for the number of rats indicated in each experiment. The data were analyzed and the figures plotted using GraphPad Prism™ (Version 5.0, GraphPad Software, San Diego, CA, USA).
Results
Effects of lead on blood pressure and heart rate
Compared to control rats, animals exposed to lead exhibited an increased SBP starting on the first week of metal exposure and beyond ( Fig. 1) .
At the end of the treatment, the animals were anesthetized, and the hemodynamic parameters were assessed in vivo. The Pb group showed a greater SBP (Ct: 122 ± 4 vs. Pb: 143 ± 3 mmHg), DBP (Ct: 63 ± 4 vs. Pb: 84 ± 4 mmHg) and HR (Ct: 299 ± 11 vs. Pb: 365 ± 11 bpm). Phenylephrine increased the SBP and DBP in both groups ( Fig. 2A and B) ; however, lead treatment decreased the sensitivity of phenylephrine on the SBP and DBP (Fig. 2C and D) .
Role of the sympathetic nervous system on increases in the arterial pressure induced by lead exposure
To evaluate the impact of the autonomic tone on the hemodynamic parameters assessed in the anesthetized animal subjected to lead treatment, the ganglionic blocker hexamethonium (20 mg/kg, IV) was used. Hexamethonium reduced the baseline SBP, DBP and HR in both groups as expected. The increases in the BP and HR induced by lead exposure after hexamethonium administration were reduced compared to the increases observed in the Ct rats (Fig. 3) .
Moreover, when testing the pressure reactivity to phenylephrine before and after hexamethonium administration, we observed a reduced DBP in the Pb group as demonstrated by the difference in the area under the curve (dAUC) values (Fig. 4 -F) . These findings suggest that lead activates the sympathetic nervous system, which leads to increased BP. In addition, lead increased the autonomic tone on peripheral vascular resistance.
Effects of lead on β-adrenergic modulation
To investigate the effects on the autonomic system, the putative changes in the β-adrenergic modulation induced by lead exposure were analyzed. The difference in the left ventricular systolic pressure (LVSP) and end-diastolic pressure (LVEDP) before and after isoproterenol administration (10 μg/kg, IV) was higher in the Ct group (Fig. 5) . The β 1 -adrenergic receptor agonist caused a greater increase of the LVSP and LVEDP in the Ct group but did not affect the pressure in the Pb group, suggesting that β 1 -adrenoceptors are downregulated after lead treatment. To reinforce this finding, western blot analysis showed reduced protein expression of β 1 -adrenoceptors in the Pb group compared to the Ct (Fig. 6) . The left ventricular positive (dP/dt + LV) and negative (dP/dt-LV) derivatives were similar to the ventricular pressure results (data not shown).
3.4. Role of the renin angiotensin system in the increases in arterial pressure induced by lead exposure Simões et al. [8] showed that acute lead exposure increases arterial pressure due to elevated renin-angiotensin system (RAS) activity. Furthermore, Vander [17] reported that chronic lead exposure promotes changes in the RAS and alters the BP as indicated by increased renin secretion.
To evaluate whether sub-chronic lead exposure affects RAS activity in vivo, an AT 1 receptor antagonist was administered. The pressure reactivity to phenylephrine was also tested before and after losartan administration. Losartan (10 mg/kg, IV) reduced the SBP and DBP in both groups (Fig. 7) .
A decrease in the DBP was also observed as demonstrated by the dAUC values, which suggests that sub-chronic lead exposure enhances the activity of the renin angiotensin system (Fig. 8 -F) .
This finding suggests that sub-chronic lead exposure enhances the activity of the renin angiotensin system, which causes a reduction in phenylephrine-induced pressure reactivity on the DBP as illustrated by the dAUC values (Fig. 8 -F) .
Effects of lead on COX activity and NO modulation
Because we have reported that lead affects COX activity [6, 7] , the COX inhibitor indomethacin was used to investigate the putative role of prostanoids in lead-treated rats. Indomethacin [(0.1 mg/kg, intravenous (IV)] did not reduce the SBP and DBP (Fig. 9) . Moreover, indomethacin did not change the pressure reactivity to phenylephrine in either group (data not shown).
To evaluate whether lead acetate treatment alters NO modulation, the effect of the NOS inhibitor L-NAME was analyzed. L-NAME (3 mg/kg, IV) increased both the SBP and DBP in the Ct group. However, lead treatment abolished or reduced the effects of L-NAME effect on the SBP and DBP (Fig. 10) , respectively. This finding suggests that lead exposure reduced NO bioavailability.
Discussion
The major findings of this study indicate that sub-chronic treatment with low concentrations of lead, i.e., lower than those reported for exposed individuals (60 μg/dL), increased the BP and decreased the percentage of the change of phenylephrine-induced pressure reactivity in rats in vivo. The BP increment seems to be caused by an increased sympathetic tone that resulted in the downregulation of cardiac β 1 -adrenoceptors, which is probably a compensatory mechanism. However, this was not an exclusive effect because RAS-and COX-derived compounds also contributed to this downregulation-losartan and indomethacin reduced the negative effects of the lead treatment. Therefore, this alteration in the BP was not only associated with enhanced autonomic activity but also with reduced NO modulation.
Previous findings showed that lead increases the BP and sympathetic tone in vivo [12, 13] and reduces NO bioavailability [18] and increases oxidative stress in vitro [10] . Therefore, we investigated the effects of sub-chronic lead exposure on blood pressure reactivity and cardiac β 1 -adrenoceptor activity and evaluated whether the effects observed in vitro are similar to those found in vivo. Lead has been considered a risk factor for the development of hypertension and other cardiovascular diseases [19] . The reference value established by the Agency for Toxic Substances and Disease Registry (ATSDR) [20] for exposed individuals corresponds to a blood lead level (BLL) of 60 μg/dL [21, 22] . Recently, the Council of State and Territorial Epidemiologists (CSTE) [23] reported that if the BLL is between 50 and 79 μg/dL, the source of metal exposure must be removed, and the person should be medically evaluated and undergo immediate treatment and should even consider chelation therapy if significant symptoms are present. It is worth mentioning that this BLL (60 μg/dL) applies to exposed workers and not the general population because this reference value is higher than that in other countries [20, 23] . This study used a model developed in our laboratory that corresponds to a BLL of~10 μg/dL, which is lower than the reference value but still induces an increase in BP [10, 16] .
Sympathetic hyperactivity induced by lead exposure
In the present study, we found an increase in the BP in the Pb group during the first week of lead exposure, which remained elevated until cessation of treatment as previously reported [10, 16] . It is interesting that the effect of lead exposure on DBP was more pronounced than that of SBP. This was expected because lead exerts a greater effect on the vascular smooth muscle, which is responsible for peripheral resistance.
Different studies have demonstrated increased BP and cardiac inotropism [12, 16] , sympathetic hyperactivity, reduced baroreflex sensitivity and vagal hypotonia [13] , suggesting that lead seems to enhance sympathetic activity via central mechanisms. When evaluating heart rate variability, cardiovascular autonomic reflexes and the sympathovagal balance on the heart, Simões et al. [24] demonstrated that rats chronically exposed to low levels of lead presented an autonomic imbalance characterized by increased sympathetic tone and reduced vagal tone. Moreover, other studies have reported increased plasma levels of noradrenaline and adrenaline in lead-exposed animals [12, 14] . Simões et al. [8] investigated the effects of acute lead exposure on hemodynamic parameters and demonstrated that the increased SBP was not modified by hexamethonium during the early stage of hypertension development. However, our results showed that hexamethonium decreased the SBP, DBP and HR in Pb-induced hypertension (Fig. 3) , suggesting that lead induces late sympathetic hyperactivity in vivo. Our results are in accordance with previous studies that observed central and peripheral sympathetic hyperactivity after lead treatment [12, 14, 25] .
These findings corroborate our results, which suggest that cardiac β 1 -adrenergic receptor activity is modulated. Compared to the Ct group, the Pb group showed a reduced response to the β-adrenergic agonists suggesting that downregulation in response to lead exposure occurs as a compensatory mechanism (Fig. 5) . To reinforce this finding, western blot analysis showed reduced protein expression of cardiac β 1 -adrenoceptors in the Pb group (Fig. 6) .
The reduction of the DBP reactivity, which is dependent on the contractile ability of the vascular smooth muscle in the resistance vessels, proceeded lead exposure. α 1 -adrenergic receptor activation by phenylephrine increased the vascular tone in both the Ct and Pb groups in a similar manner, which explains this reduction in DBP reactivity. This response would be different if the vascular smooth muscles were affected Fig. 4 . Role of autonomic reflexes on the effects of lead on reactivity pressure. Concentration-response curves to phenylephrine in SBP in the control group (A), before (Ct) and after administration of hexamethonium (Ct Hexa), and in the group exposed to lead (B), before (Pb) and after administration of hexamethonium (Pb Hexa). Concentration-response curves to phenylephrine in DBP in the control group (D), before (Ct) and after administration of hexamethonium (Ct Hexa), and in the group exposed to lead (E), before (Pb) and after administration of hexamethonium (Pb Hexa) (Ct and Ct Hexa, N = 5; Pb and Pb Hexa, N = 8). Percentage difference of the area under the curve in SBP (C) and DBP (F) before and after administration of hexamethonium between groups. Data are presented as the mean ± SEM. For statistical analysis, two-way ANOVA followed by Bonferroni's post-test was used. Student's t-test was used to analyse the percentage difference in the area under the curve (dAUC). *P b 0.01 vs. Ct; by lead. Reinforcing this observation, previous reports using similar lead concentrations in aortic rings showed no differences between the control and lead-treated rings when the preparations were depolarized using 120 mM potassium chloride (KCl). In addition, the relaxation produced by sodium nitroprusside (NPS) was similar in both groups [6] .
It is worth mentioning that exposure to lower levels of lead could initially promote reduced systolic, diastolic and pulse pressure and dilatation of the carotid artery [26] . Consequently, sympathetic stimulation mediated by the baroreceptor compensation mechanism can maintain BP. Thus, higher doses of lead significantly increased the DBP and SBP without affecting the pulse pressure [26] .
Hexamethonium reduced the pressure reactivity to phenylephrine in the Pb group by affecting the DBP as demonstrated by the dAUC values (Fig. 4 -F) . Moreover, the ganglionic blockade caused a reduction in the sensitivity to the lower doses of the phenylephrine dose-response curve; however, it did not change the maximal response of DBP (Fig. 4) . This finding suggests that only the effects of the lower doses of phenylephrine were mitigated by ganglionic blockade. However, exposure to high doses of phenylephrine saturated the α 1 -receptors, and hexamethonium thus did not alter the maximum response.
Activity of the renin angiotensin system in lead exposure
Because sympathetic activation via β-adrenoceptors stimulates renal renin release [27] we investigated the participation of the RAS on the effects of lead exposure. An AT 1 receptor blocker was used. Losartan reduced the SBP and DBP (Fig. 7) , suggesting that angiotensin II is involved in the effects of sub-chronic lead exposure.
Previous reports showed that lead increased the SBP followed by an elevation of plasma ACE activity without changing the AT 1 and AT 2 protein expression levels in the aorta [9, 8] . These in vitro findings corroborate our in vivo results because losartan reduced the SBP and DBP and induced a reduction in DBP reactivity as demonstrated by the dAUC values ( Fig. 8 -F) . Similarly, losartan caused a reduction in the sensitivity to the lower doses of phenylephrine in the dose-response curve but did not alter the maximal response (Fig. 8) . These effects might be mediated by a reduced pressor effect of angiotensin II on AT 1 receptors. Another mechanism for this reduction could be the possible AT 2 receptor stimulation by angiotensin II because losartan blocks AT 1 receptor stimulation [28, 29] , although we have not investigated this possibility. In contrast, using a model of exposure to lead, methylmercury and inorganic mercury via drinking water for 4 weeks, Wildemann et al. [30] observed that the effect of lead on the RAS activity was not as significant as the effects caused by methylmercury, which resulted in increased angiotensin II levels. However, it cannot be disregarded that Pb could exert a transient effect on RAS after 4 weeks of exposure. When the metals were simultaneously administered, the effect of Pb on oxidative stress persisted in relation to the other metals [30] . However, the effect of methylmercury on RAS did not persist, suggesting a dissociation between the mechanisms of oxidative stress and RAS in hypertension [30] .
Vascular tone modulation induced by lead
The regulation of vascular smooth muscle tone is governed by endothelium-derived factors, blood flow, vessel innervation and hormonal stimulation [31, 32, 33] . We previously showed that lead exposure causes changes in vascular tone associated with the reduced activation nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and cyclooxygenase 2 (COX-2) [7] , increased participation of COX-derived contractile prostanoids [7, 9] , reduced NO bioavailability [9, 18] and increased ROS production [9, 34] . In a previous study, Silveira et al. [35] showed that lead induces vasoconstrictor effects in the rat tail artery that were abolished by indomethacin administration, suggesting that lead might stimulate the release of COX-derived vasoconstrictor prostanoids. Simões et al. [7] demonstrated that lead activates mitogen activated protein kinases (MAPK) signaling pathways associated with the activation of inflammatory proteins such as NADPH oxidase and Fig. 8 . Role of the Renin Angiotensin System on the effects of lead on reactivity pressure. Concentration-response curves to phenylephrine in SBP in the control group (A), before (Ct) and after administration of Losartan (Ct Los), and in the group exposed to lead (B), before (Pb) and after administration of Losartan (Pb Los). Concentration-response curves to phenylephrine in DBP in the control group (D), before (Ct) and after administration of Losartan (Ct Los), and in the group exposed to lead (E), before (Pb) and after administration of Losartan (Pb Los) (Ct and Ct Los, N = 8; Pb and Pb Los, N = 11). Percentage difference in the area under the curve in SBP (C) and DBP (F), before and after administration of Losartan between groups. Data are presented as the mean ± SEM. For statistical analysis, two-way ANOVA followed by Bonferroni's post-test was used. Student's t-test was used to analyse the percentage difference in the area under the curve (dAUC).*P b 0.01 vs. Ct; COX-2, thus highlighting the contribution of MAPKs to vascular dysfunction as an underlying mechanism for lead-induced hypertension. Our results showed that indomethacin reduced BP (Fig. 9 ) but did not alter the pressure reactivity to phenylephrine (data not shown), suggesting that lead promotes the production of COX-derived prostanoids that might contribute to the development of hypertension.
These effects can also be mediated by increased vascular tone, which also appears to be related to the reduction of NO bioavailability [9, 18, 36, 37] . Lead exposure decreases NO production [9, 10, 11] , which may contribute to the increased vascular reactivity to phenylephrine. Our in vivo results demonstrated that L-NAME increased the BP in both experimental groups; however, the magnitude of this effect was smaller in the Pb group as indicated by the ΔDBP (Fig. 10B and D) . This result suggests that lead reduces NO bioavailability as previously reported [7] .
Conclusion
In conclusion, we found that sub-chronic exposure to low doses of lead increased the BP and HR and decreased blood pressure reactivity at lower concentrations of phenylephrine in vivo, which were similar to the results obtained in vitro. These changes were associated with increased sympathetic tone, increased RAS mediated by AT1 receptor activation and reduced NO bioavailability. Moreover, changes in the sympathetic tone promote the downregulation of cardiac β 1 -adrenoceptors-probably as a compensatory mechanism. These findings also demonstrated that lead concentrations below the BLL cut-off for lead poisoning might be considered an important risk factor for cardiovascular diseases and provide guidelines for reviewing the lead concentrations that are currently considered safe. Fig. 9 . Involvement of the cyclooxygenase pathway in the hemodynamic changes induced by lead. SBP (A) and DBP (B) before, in the control group (Ct) and treated group (Pb), and after administration of Indomethacin, in the control group (Ct Indo) and in the treated group (Pb Indo) (Ct and Ct Indo, N = 8; Pb and Pb Indo, N = 11). Data are presented as the mean ± SEM. For statistical analysis, one-way ANOVA followed by Tukey's post-test was used. *P b 0.05 vs. Ct. Fig. 10 . Influence of the bioavailability of nitric oxide on the hemodynamic changes induced by lead. SBP (A) and DBP (B) before, in the control group (Ct) and treated group (Pb), and after L-NAME administration in the control group (Ct L-NAME) and treated group (Pb L-NAME). The pressure variation was calculated by the difference between the values of SBP (C) represented by ΔSBP, and DBP (D), represented by ΔDBP, before and after L-NAME administration in each group (N = 7). Data are presented as the mean ± SEM. For statistical analysis, we was used Student's t-test and one-way ANOVA followed by Tukey's post-test. *P b 0.05 vs. Ct L-NAME; & P b 0.05 vs. Pb; + P b 0.05 vs. Ct L-NAME.
